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Alzheimer’s disease (AD) is a progressive disorder that affects cognitive brain functions and starts many years before its clinical
manifestations. A biomarker that provides a quantitative measure of changes in the brain due to AD in the early stages would
be useful for early diagnosis of AD, but this would involve dealing with large numbers of people because up to 50% of dementia
sufferers do not receive formal diagnosis.Thus, there is a need for accurate, low-cost, and easy to use biomarkers that could be used
to detect AD in its early stages. Potentially, electroencephalogram (EEG) based biomarkers can play a vital role in early diagnosis
of AD as they can fulfill these needs. This is a cross-sectional study that aims to demonstrate the usefulness of EEG complexity
measures in early AD diagnosis. We have focused on the three complexity methods which have shown the greatest promise in the
detection of AD, Tsallis entropy (TsEn), Higuchi Fractal Dimension (HFD), and Lempel-Ziv complexity (LZC) methods. Unlike
previous approaches, in this study, the complexity measures are derived from EEG frequency bands (instead of the entire EEG) as
EEG activities have significant association with AD and this has led to enhanced performance. The results show that AD patients
have significantly lower TsEn, HFD, and LZC values for specific EEG frequency bands and for specific EEG channels and that this
information can be used to detect AD with a sensitivity and specificity of more than 90%.
1. Introduction
Alzheimer’s disease (AD) is an age-related progressive, neu-
rodegenerative disorder that is characterized by loss of
memory and cognitive decline [1, 2] and it is the main
cause of disability among older people [3]. AD is ranked
as the sixth leading cause of death in US [4]. The rapid
increase in the number of people living with AD and other
forms of dementia due to the ageing population represents a
major challenge to health and social care systems worldwide
[5]. Currently, there are over 46.8 million individuals with
dementia worldwide with an annual cost of care estimated
at US$818 billion and is projected to reach 74.7 million by
2030 with an annual cost of US$2 trillion [6]. The number of
individuals with dementia worldwide is expected to exceed
131 million by 2050 which will have a huge economic impact
[7]. However, many dementia sufferers do not receive early
diagnosis [7, 8]. It is estimated that up to 50% of people living
with dementia may not have received formal diagnosis [8, 9].
In 2011, 28million people of 36million dementia sufferers did
not receive a diagnosis worldwide [10].
Degeneration of brain cells due to AD starts many years
before the clinical manifestations become clear [5, 11–15]. An
early diagnosis of AD will contribute to the development
of effective treatments that could slow, stop, or prevent
significant cognitive decline [16–18]. An early diagnosis of
AD could also be useful for identifying dementia sufferers
who have not received a formal early diagnosis and this may
provide an opportunity for them to access appropriate health
care services [19–21].
A biomarker that can measure degeneration of brain
cells due to AD at an early stage would be useful for its
early diagnosis [2, 22–24]. But this may require dealing with
large numbers of people as up to 50% of people living with
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dementia may not have received a formal diagnosis. There-
fore, there is a need for simple, noninvasive, low-cost, and
reliable biomarkers for early diagnosis which can be accessed
in clinical practice [5, 25, 26]. Recent guidelines promote the
use of biochemical and neuroimaging biomarkers to improve
the diagnosis of AD. Cerebral spinal fluid (CSF) testing for
AD is not widely used in clinical practice because it requires
lumbar puncture which is an invasive procedure [2, 27,
28]. Neuroimaging is expensive, available only in specialist
centres [29], and may not be suitable for patients that have
pacemakers or certain implants [30]. Blood-based biomark-
ers have shown promising results in AD diagnosis but they
are not yet fully developed and low-cost biosensors to detect
AD biomarkers in blood do not exist at present [2, 25, 31].
Potentially, the electroencephalogram (EEG) can play a
valuable role in the early diagnosis of AD [11, 20, 21, 24,
32–34]. EEG is noninvasive, low-cost, has a high temporal
resolution, and provides valuable information about brain
dynamics in AD [20, 21, 33, 35, 36]. The fundamental utility
of EEG to detect brain signal changes even in the preclinical
stage of the disease has been demonstrated [33, 37, 38]. Thus,
EEG biomarkers may be used as a first-line decision-support
tool in ADdiagnosis [11, 35] and could complement other AD
biomarkers [26].
AD is characterized by loss of memory and cognitive
decline resulting from damage to brain cells which influence
brain activity [38]. AD causes changes in the features of the
EEG [35, 38, 39] andEEGanalysismay provide valuable infor-
mation about brain dynamics due to AD [20, 21, 33, 35]. The
most characteristic features in EEG caused by AD are slowing
of EEG, a decrease in EEG coherence, and reduction in EEG
complexity [33–35, 37, 38, 40, 41]. These changes in the EEG
can be quantified as a biomarker ofAD.A variety of linear and
nonlinear methods are being developed to quantify changes
in EEG as AD biomarkers [42, 43]. AD biomarkers based on
the slowing in EEG and a decrease in EEG coherence are often
derived using linear analysis methods (i.e., spectral analysis
of the EEG signal) [37, 44, 45], while biomarkers extracted by
analysing the complexity of the EEG are based on nonlinear
approaches (e.g., entropy methods, fractal dimension, and
Lempel-Ziv complexity). The EEG complexity approaches
have shown promising results in AD diagnosis [11, 35, 46]
and appear to be appropriate for AD diagnosis [38, 47, 48].
Complexity is a measure of the extent to which the dynamic
behavior of a given sequence resembles a random one [49].
The cortical areas of the brain fire spontaneously and this
dynamic behavior of the brain is complex [50, 51]. AD causes
a reduction in neuronal activity of the brain [52] resulting
in decreased capability of the brain to process information
[53–55] and this may be reflected in the EEG signals [52].
EEG complexity can potentially be a good biomarker for AD
diagnosis [38] as AD patients have a significant reduction in
EEG complexity [38, 40, 41, 52, 56, 57]. Several studies have
investigated EEG complexity as a potential AD biomarker
using whole EEG record with the objective of achieving a
high performance. Given the association of EEG activities
(e.g., alpha, delta activities) with AD, we hypothesized that
the derivation of EEG complexity based on EEG activities
should lead to enhanced performance.
This is a cross-sectional study aimed at demonstrating the
usefulness of EEG based complexity measures to detect AD.
In this study, we investigated an important class of complexity
measures, information theoretic methods, which offers a
potentially powerful approach for quantifying changes in
the EEG due to AD [58]. Information theoretic methods
(i.e., TsEn and LZC) have emerged as a potentially useful
complexity-based approach to derive robust EEG biomarkers
of AD [47, 58–62].They are attractive because of the potential
natural link between information theory-based biomarkers
and changes in the brain caused by AD [58]. Conceptually,
information processing activities in the brain are thought to
be reflected in the information content of the EEG.
In particular, TsEn approach has been shown to be one
of the most promising information theoretic methods for
quantifying changes in the EEG [62, 63]. It has also been
shown to be a reliable analysis tool to use with working
memory tasks. As its computation is fast, it can serve as a basis
for a real-time decision-support tool for dementia diagnosis
by both specialists and nonspecialists [64]. Sneddon et al.
[65] investigated TsEn of the EEG and was able to detect
mild dementia due to AD with a sensitivity of 88% and
specificity of 94%. De Bock et al. [62] found TsEn of the
EEG to be a highly promising potential diagnostic tool for
mild cognitive impairment (MCI) and early dementia with
a sensitivity and specificity of 82% and 73%, respectively.
Using TsEn approach, Al-Nuaimi et al. [35] detectedAD from
normal subjects with a sensitivity and specificity of 85.8% and
70.9%, respectively. Garn et al. [66] investigated the use of
TsEn to diagnose AD based on EEG analysis and achieved a𝑝 value < 0.0036 for channels T7 and T8 in discriminating
between AD patients and normal subjects.
LZC is a nonparametric, nonlinearmeasure of complexity
for finite length sequences [67]. It is a simple and powerful
method which has been used in several biomedical applica-
tions [68]. LZC depends on a coarse-grain processing of the
measurements [69] and can be applied directly on physiologic
signal without preprocessing [70]. LZC has been applied
extensively in analysing biomedical signals (e.g., EEG) to
measure the complexity of discrete-time physiologic signals
[67]. Furthermore, it is used to analyse brain function, brain
information transmission, and EEG complexity in patients
with AD [43].The LZC approach produces a good biomarker
for AD detection [70, 71]. Hornero et al. [72] used LZC
to analyse EEG and magnetoencephalogram (MEG) in AD
patients. They found that LZC provides a good insight into
the EEG background activity characteristics and the changes
associated with AD. Hornero et al. [73] found that LZC
values were lower in AD patients and suggested that the most
relevant differences are in the posterior region. In addition,
they suggested that the MEG activity from AD patients is
characterized by a lower degree of irregularity and complexity
and that the LZC measures can be used to detect AD with a
sensitivity and specificity values of 65% and 76.2%, respec-
tively. McBride et al. [56] analysed EEG complexity based
on the LZC method to discriminate between patients with
earlyMCI, ADpatients, and normal subjects.They found that
EEG complexity features for specific EEG frequency bands
with regional electrical activity provide promising results
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in discriminating between MCI, AD, and normal subjects.
Fernandez et al. [74] analysed MEG complexity for MCI
patients, AD patients, and normal subjects based on LZC
method for discriminating between the three groups. They
found that a combination of age and posterior LZC scores
allowed them to distinguish between AD patients and MCI
patients with 94.4% sensitivity and specificity.
HFD is a fast computational method for obtaining the
fractal dimension of time series signals [75–77] even when
very few data points are available [75]. It can track changes
in a biosignal from a measure of its complexity [75, 76]
and it is suited to capturing region-specific neural changes
due to AD [45, 77]. In addition, HFD provides a more
accurate measure of the complexity of signals compared to
other methods [75, 78, 79] and it has been shown to be an
efficient method for discriminating between AD patients and
normal subjects [31, 80]. HFD of the EEG is potentially a
good biomarker of AD diagnosis as it is significantly lower
in AD patients than in normal subjects [46, 80, 81]. Smits et
al. found that HFD is sensitive to neural changes selectively
related to AD patients and normal subjects. Al-Nuaimi et al.
[46] investigated HFD of EEG for AD diagnosis and they
found that HFD is a promising EEG biomarker that captures
changes in the regions of the brain thought to be affected first
by AD and it could be used to detect AD with sensitivity and
specificity values of 100% and 80%, respectively.
It is widely accepted that AD causes a decrease in the
power of high frequencies (alpha, beta, and gamma) and an
increase in the power of low frequencies (delta and theta)
[11, 33, 34, 38, 41].We hypothesized that complexity measures
based on the EEG frequency bands would provide better
results than those derived directly from the whole EEG
record. The aim was to enhance the performance of the
complexity measures and to demonstrate their usefulness in
quantifying changes in EEG due to AD.
Digital filters were used to extract the five EEG frequency
bands (i.e., delta, theta, alpha, beta, and gamma). Complexity
measures were then obtained for each of the five EEG
frequency bands and for each channel using each of the three
methods of computing complexity measures (TsEn, HFD,
and LZC).
For each method, we computed a panel of 114 biomark-
ers (i.e., 19 biomarkers for the whole EEG record and 19
biomarkers for each of the five EEG frequency bands). The
performance measures for each biomarker were computed
(including the sensitivity and specificity).
The paper is arranged as follows. In Section 2, the
materials and methods used in the study are described. In
Section 3, the results and discussions are presented and the
conclusions are presented in Section 4.
2. Materials and Methods
2.1. Materials. This study was based on EEG dataset that was
recorded from 52 volunteers. All the volunteers underwent
a strict protocol based on normal hospital practices at
Derriford Hospital, Plymouth, UK [11]. The EEG record-
ings include several states such as hyperventilation, awake,
drowsy, and alert, with periods of eyes closed and open. For
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Figure 1: International 10–20 system.
storage reasons, the sampling rate was reduced from 256Hz
to 128Hz by averaging two consecutive samples.The duration
of each EEG signal is 4 minutes. Figure 1 shows the electrode
locations using a 10–20 system. The letters F, C, P, O, and T
refer to cerebral cortex lobes (F: frontal, C: central, P: parietal,
O: occipital, and T: temporal) [82].
The EEG dataset consists of two subdatasets (A and B).
Subdataset A includes 11 age matched subjects over 65 years
old (3 AD patients and 8 normal subjects). Subdataset A was
recorded using the traditional 10–20 system in a Common
Reference Montage by using the average of all channels as
reference and the EEG signals were converted to Common
Average and Bipolar Montages using software. Subdataset B
includes 41 subjects that were not perfectly age matched (24
normal subjects, 10 males and 14 females, have mean age 69.4± 11.5 years (from 40 to 84 years) and 17 were probable AD
patients, 9 male and 8 female). The normal subjects have
a mean age of 69.4 ± 11.5 years (40 to 84 years) and the
probable AD subjects have mean age of 77.6 ± 10.0 years
(from 50 to 93 years). Subdataset B was recorded using the
modified Maudsley system. The conventional 10–20 system
has a similar setting with the Maudsley electrode positioning
system [83].
All patients were referred to the EEG department at
DerrifordHospital from a specialist memory clinic. A battery
of psychometric tests (including the MMSE [84], Rey Audi-
tory Verbal Learning Test [85], Benton Visual Retention Test
[86], and memory recall tests [87]) were performed on all
patients at the memory clinic. The classification of subjects
with dementia was based on the working diagnosis provided
by the specialist memory clinic. All healthy volunteers and
AD patients had their EEG confirmed by a consultant clinical
neurophysiologist at the hospital as normal and probable
mild AD, respectively [11].
2.2. Methods. In our approach, the complete recordings of
the EEG including artefacts were used without a priori
selection of elements for analyses. This enabled us to have
an idea about the robustness and usefulness of the method
in practice. Data from a fixed interval (61 s to 240 s) was
used to avoid electrical artefacts, which regularly occur at the
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beginning of a record, leaving a standard three-minute data
to analyse.
The following steps outline the procedure that was used to
derive the biomarkers for the three complexity methods (i.e.,
TsEn, HFD, and LZC)
(1) The EEG signal was filtered using infinite impulse
response (IIR) Chebyshev-II bandpass filter into five
frequency bands (i.e., delta 0–4Hz, theta 4–8Hz,
alpha 8–12Hz, beta 12–30Hz, and gamma 30–45Hz).
A low computational IIR filter was used to retain the
computational efficiency of the derived complexity-
based biomarkers [88].
(2) The biomarkers were then derived first from the
whole EEG record and then for each of EEG fre-
quency bands for each of the three EEG complexity
methods.
(3) For each biomarker of the EEG complexity methods
(i.e., TsEn, HFD, and LZC), 𝑝 values were computed
between AD patients and normal subjects using
Student’s 𝑡-test.
(4) The performance of each complexity measure to
detect AD is then assessed. For each complexity
measure, a classification model, based on the support
vector machine (SVM), was used to detect AD.
Tsallis Entropy (TsEn). TsEn [89] biomarker computation
of an 𝑁-samples EEG data sequence 𝑥(1), 𝑥(2), . . . , 𝑥(𝑁) is
based on the generalised measure of entropy, due to Tsallis:
TsEn𝑞 = (∑
𝑘
𝑖=1 𝑃𝑖 − 𝑃𝑞𝑖 )(𝑞 − 1) , (1)
where TsEn𝑞 is the Tsallis entropy value, 𝑘 is the number of
states that the amplitudes of the EEG are quantized into, 𝑃𝑖
is a probability associated with the 𝑖th state, and 𝑞 is Tsallis
parameter (𝑘 = 2200 and 𝑞 = 0.5).
Higuchi Fractal Dimension (HFD). To compute HFD
biomarker [75, 77, 90] of an 𝑁-sample EEG data sequence𝑥(1), 𝑥(2), . . . , 𝑥(𝑁), the data is first divided into a 𝑘-length
subdata set as
𝑥𝑚𝑘 : 𝑥 (𝑚) , 𝑥 (𝑚 + 𝑘) , 𝑥 (𝑚 + 2𝑘) , . . . ,
𝑥 (𝑚 + [𝑁 − 𝑚𝑘 ] ⋅ 𝑘) ,
(2)
where [ ] is Gauss’ notation, 𝑘 is constant, and𝑚 = 1, 2, . . . , 𝑘.
The length 𝐿𝑚(𝑘) for each subdata set is then computed as
𝐿𝑚 (𝑘)
= {[[(𝑁−𝑚)/𝑘]∑
𝑖=1
|𝑥 (𝑚 + 𝑖𝑘) − 𝑥 (𝑚 + (𝑖 − 1) ⋅ 𝑘)|]
⋅ ((𝑁 − 1) / ([(𝑁 − 𝑚) /𝑘] ⋅ 𝑘))} ⋅ (𝑘)−1 .
(3)
The mean of 𝐿𝑚(𝑘) is then computed to find the HFD for the
data as
HFD = 1𝐾
𝐾∑
𝑀=1
𝐿𝑚 (𝑘) . (4)
Lempel-Ziv Complexity (LZC). To compute the LZC [43, 49,
67, 68, 70] biomarker of an 𝑁-sample EEG data sequence𝑥(1), 𝑥(2), . . . , 𝑥(𝑁), the EEG signal is first converted into a
binary string as
𝑥 (𝑖) = {{{
0 if EEG (𝑖) < 𝑀
1 if EEG (𝑖) ≥ 𝑀, (5)
where 𝑥(𝑖) is the equivalent binary value of EEG(𝑖), 𝑖 is the
index of all values in the EEG signal, and 𝑀 is the median
value of each EEG channel. The median value is used to
manage the outliers.
The binary string is then scanned from left to right until
the end to produce new substrings. A complexity counter𝑐(𝑁) is the number of new substrings. The upper bound of𝑐(𝑁) is used to normalise 𝑐(𝑁) to get an independent value
from the sequence of length 𝑁. The upper bound of 𝑐(𝑁) is𝑁/log2(𝑁). 𝑐(𝑁) is then normalised by 𝑏(𝑁) as
𝐶 (𝑁) = 𝑐 (𝑁)𝑏 (𝑁) , (6)
where 𝐶(𝑁) is the normalised value of the LZC and 𝑏(𝑁) is
the upper bound of the 𝑐(𝑁).
A panel of 114 biomarkers was computed (19 biomarkers
for the whole EEG record and 19 biomarkers for each of EEG
frequency band (i.e., delta, theta, alpha, beta, and gamma). To
determine which features have a significant statistical associ-
ation with AD, we computed 𝑝 values between AD patients
and normal subjects using Student’s 𝑡-test. This allowed us to
identify significant features thatmay be useful to discriminate
between AD patients and normal subjects. The dataset was
split into training and testing data (60% for training and 40%
for testing) with subjects selected at random. We selected 32
subjects for training and 20 subjects for testing at random
from the datasets, a ratio of 60 : 40.The training data includes
12 AD (two from dataset A and 10 from dataset B) and 20
normal subjects (six from dataset A and 14 from dataset B).
The testing data includes 8 AD (one from dataset A and
seven from dataset B) and 12 normal subjects (two from
dataset A and 10 from dataset B). 𝑝 values were computed
using the training EEG dataset. Machine learning techniques
were used to develop models based on the biomarkers.
As a classifier, we used support vector machine (SVM) to
model biomarkers extracted using TsEn, HFD, and LZC
methods. SVM classifier was used because it is widely used
in machine learning and has found application in dementia
diagnosis. It has shown better performance in biomedical
data analysis and in automatic AD diagnosis compared to
other conventional classifiers (e.g., Euclidean distance clas-
sifier) and good capability to learn from experimental data
[91, 92], and it has a stable classification performance [93].
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It has also been shown to outperform other machine learning
techniques (e.g., Naive Bayes, Multilayer Perceptron, Bayes
Network, egging, Logistic Regression, and Random Forest,)
in diagnosis of MCI and dementia [94]. We used the testing
EEG dataset to test the performance of the models. For
each complexitymethod, six performance tables were created
(whole EEG record, and table for each EEG frequency band).
The performance of the TsEn, HFD, and LZC biomarkers
for AD diagnosis was assessed in terms of sensitivity (Sen),
specificity (Spec), accuracy (ACC), 𝐹-measure, error rate,
true positive rate (TPR), false positive rate (FPR), positive
predictive value (PPV), and negative predictive value (NPV).
Matthew’s correlation coefficient (MCC) was computed to
measure the quality of the binary classification (AD and
normal) between the actual and predicted results [95, 96].
3. Results and Discussions
3.1. Result. We analysed the performance of the three dif-
ferent complexity measures in quantifying changes in EEG
due to AD. For this purpose, we examined the differences
between the values of the complexity measures derived from
EEG signals of AD subjects and those of normal subjects.
Biomarkers that do not show significant differences between
AD patients and normal subjects may not be suitable for
quantifying changes in EEG due to AD as they may not be
capable of being used to discriminate between AD patients
and normal subjects.
We found that complexity measures derived from the
EEG frequency bands for AD patients were significantly
different to those of normal subjects compared to complexity
measures derived from the whole EEG record. This suggests
that they may be better suited to quantify changes in the EEG
due to AD and potentially may provide better results in AD
diagnosis.
Figure 2 shows the EEG biomarkers derived from whole
EEG record (i.e., unfiltered) and those derived from the five
EEG bands (delta, theta, alpha, beta, and gamma bands)
using the TsEn method. The results show that TsEn values
for AD patients are lower than those for normal subjects for
whole EEG record. This is consistent with the findings in
other studies [35, 58, 62, 64]. Figure 2 also shows that the
differences between the TsEn values for AD patients and for
normal subjects for the EEG bands (delta and theta bands
in particular) are larger than those for whole EEG record.
This is a desirable feature in a biomarker as it suggests that
TsEn biomarkers derived from the EEG bands may provide
better performance in detecting AD than those extracted
from whole EEG record.
Figure 3 shows the EEG biomarkers derived from whole
EEG record and those derived from the EEG bands (delta,
theta, alpha, beta, and gamma bands in particular) using the
HFD method. In this case, the results show that HFD values
for AD patients are lower than those for normal subjects.
This result is consistent with the finding in other studies
[46, 80]. As with the TsEn, the differences between HFD
biomarkers for AD patients and normal subjects for the EEG
frequency bands (i.e., delta, theta, and alpha bands) were
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Figure 2: EEG biomarkers for TsEn.
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Figure 3: EEG biomarkers for HFD.
larger than those for thewhole EEG record suggesting that the
use of biomarkers derived from the frequency bandswould be
better at detecting AD than the use of whole EEG record.
Figure 4 shows similar results for the LZC method. In
this case, the results show that LZC values for AD patients
were lower than those for normal subjects and these are
consistent with the finding in other studies [43, 97]. Again,
the differences between the LZC biomarkers for AD patients
and normal subjects for the five EEG frequency bands (the
theta, beta, and gamma bands, in particular) were larger
those for the whole EEG record, suggesting that the use
of biomarkers derived from the frequency bands would be
better at detecting AD than the use of whole EEG record.
We analysed the complexity measures using 𝑝 values to
determine the statistical significance in detecting AD
Figure 5 shows 𝑝 values of the differences in TsEn
measures betweenADpatients and normal subjects for whole
EEG record and those from the EEG frequency bands. The
results show that TsEn biomarkers that were extracted from
theta bands have the smallest 𝑝 values, while the TsEn
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Figure 4: EEG biomarkers for LZC.
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Figure 5: 𝑝 values for TsEn between AD patients and normal
subjects of the training EEG dataset.
biomarkers derived from gamma band have the maximum𝑝 value between AD patients and normal subjects. This
suggests that biomarkers that are extracted from theta band
may provide the best performance in AD diagnosis. Figure 5
also shows that biomarkers that were extracted from EEG
frequency bands may have a more significant association
with AD than the EEG biomarkers that are derived from
whole EEG record based on 𝑝 value analysis. Therefore, the
complexity measures derived from the EEG frequency band
may provide better results in the classification between AD
patients and normal subjects.
Figures 6 and 7 depict the results of similar 𝑝 value
analysis for HFD and LZCmeasures, respectively.The results
show that, in both HFD and LZC methods, the complexity
measures derived from the EEG frequency bands, theta band
have significantly smaller 𝑝 values compared to those of
measures derived from the whole EEG record. In both meth-
ods, complexity measures derived from the theta band gave
the smallest 𝑝 value. This implies that biomarkers derived
from the frequency bands, the theta band in particular, may
provide the best possible performance in AD diagnosis using
the HFD and LZC methods.
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Figure 6: 𝑝 values for HFD between AD patients and normal
subjects of the training EEG dataset.
Fp
1
Fp
2 F7 F3 FZ F4 F8 T3 C3 CZ C
4 T4 T5 P3 PZ P
4 T6 O
1
O
2
EEG channel—LZC values 
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
p
 v
al
ue
Delta
Theta
Alpha
Beta
Gamma
Whole EEG record
Figure 7: 𝑝 values for LZC between AD patients and normal
subjects of the training EEG dataset.
Looking across all the results (Figures 5, 6, and 7), the
theta band has a minimum 𝑝 value between AD patients and
normal subjects for all three complexity methods (i.e., TsEn,
HFD, and LZC). Thus, EEG biomarkers derived from EEG
frequency bands are better than the biomarkers that were
extracted from whole EEG record. The biomarkers derived
from theta band may provide the best performance in AD
diagnosis across all three methods.
3.2. The Performance of the EEG Complexity-Based Measures.
Table 1 shows the performance of the SVM-based classifi-
cation model using TsEn biomarkers for whole EEG record
for the 19 EEG channels. In this case, the best sensitivity and
specificity were 46.67% and 80%, respectively, for Fp2 and F7
EEG channels.
Similar performance indices were computed for each of
the five EEG bands using the TsEn. As an example, Table 2
shows the performance indices for TsEn biomarkers for the
delta band for the 19 EEG channels. The best sensitivity and
specificity were 85.71% and 84.62%, respectively, for T4, O1,
and O2 EEG channels.
Similar performance indices were computed for each of
the five EEG bands using HFD and LZC methods. Table 3
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Table 1: TsEn performance for whole EEG record.
EEG channel Sen.% Spec.% Acc.% 𝐹-measure% Error rate MCC FPR% FNR% PPV% NPV%
Fp1 43.75 75.00 50.00 58.33 0.50 0.153 25.00 56.25 87.50 25.00
Fp2 46.67 80.00 55.00 60.87 0.45 0.236 20.00 53.33 87.50 33.33
F7 46.67 80.00 55.00 60.87 0.45 0.236 20.00 53.33 87.50 33.33
F3 43.75 75.00 50.00 58.33 0.50 0.153 25.00 56.25 87.50 25.00
FZ 44.44 100.00 50.00 61.54 0.50 0.272 0.00 55.56 100.00 16.67
F4 44.44 100.00 50.00 61.54 0.50 0.272 0.00 55.56 100.00 16.67
F8 44.44 100.00 50.00 61.54 0.50 0.272 0.00 55.56 100.00 16.67
T3 37.50 50.00 40.00 50.00 0.60 −0.102 50.00 62.50 75.00 16.67
C3 35.71 50.00 40.00 45.45 0.60 −0.134 50.00 64.29 62.50 25.00
CZ 42.11 100.00 45.00 59.26 0.55 0.187 0.00 57.89 100.00 8.33
C4 44.44 100.00 50.00 61.54 0.50 0.272 0.00 55.56 100.00 16.67
T4 35.29 33.33 35.00 48.00 0.65 −0.229 66.67 64.71 75.00 8.33
T5 33.33 50.00 40.00 40.00 0.60 −0.167 50.00 66.67 50.00 33.33
P3 28.57 33.33 30.00 36.36 0.70 −0.356 66.67 71.43 50.00 16.67
PZ 37.50 50.00 40.00 50.00 0.60 −0.102 50.00 62.50 75.00 16.67
P4 35.71 50.00 40.00 45.45 0.60 −0.134 50.00 64.29 62.50 25.00
T6 26.67 20.00 25.00 34.78 0.75 −0.471 80.00 73.33 50.00 8.33
O1 27.27 44.44 35.00 31.58 0.65 −0.287 55.56 72.73 37.50 33.33
O2 30.00 50.00 40.00 33.33 0.60 −0.204 50.00 70.00 37.50 41.67
Table 2: TsEn performance for delta band of the EEG signal.
EEG channel Sen.% Spec.% Acc.% 𝐹-measure% Error rate MCC FPR% FNR% PPV% NPV%
Fp1 50.00 66.67 60.00 50.00 0.40 0.167 33.33 50.00 50.00 66.67
Fp2 50.00 62.50 60.00 33.33 0.40 0.102 37.50 50.00 25.00 83.33
F7 55.56 72.73 65.00 58.82 0.35 0.287 27.27 44.44 62.50 66.67
F3 80.00 73.33 75.00 61.54 0.25 0.471 26.67 20.00 50.00 91.67
FZ 50.00 62.50 60.00 33.33 0.40 0.102 37.50 50.00 25.00 83.33
F4 50.00 61.11 60.00 20.00 0.40 0.068 38.89 50.00 12.50 91.67
F8 57.14 69.23 65.00 53.33 0.35 0.257 30.77 42.86 50.00 75.00
T3 71.43 76.92 75.00 66.67 0.25 0.471 23.08 28.57 62.50 83.33
C3 60.00 66.67 65.00 46.15 0.35 0.236 33.33 40.00 37.50 83.33
CZ 100.00 63.16 65.00 22.22 0.35 0.281 36.84 0.00 12.50 100.00
C4 71.43 76.92 75.00 66.67 0.25 0.471 23.08 28.57 62.50 83.33
T4 85.71 84.62 85.00 80.00 0.15 0.685 15.38 14.29 75.00 91.67
T5 80.00 73.33 75.00 61.54 0.25 0.471 26.67 20.00 50.00 91.67
P3 75.00 83.33 80.00 75.00 0.20 0.583 16.67 25.00 75.00 83.33
PZ 100.00 75.00 80.00 66.67 0.20 0.612 25.00 0.00 50.00 100.00
P4 83.33 78.57 80.00 71.43 0.20 0.579 21.43 16.67 62.50 91.67
T6 83.33 78.57 80.00 71.43 0.20 0.579 21.43 16.67 62.50 91.67
O1 85.71 84.62 85.00 80.00 0.15 0.685 15.38 14.29 75.00 91.67
O2 85.71 84.62 85.00 80.00 0.15 0.685 15.38 14.29 75.00 91.67
summarises the best performance indices for the three
complexity measures.
Figures 8, 9, and 10 summarise the performance indices
of the TsEn, HFD, and ZLC methods.
The results show that TsEn, HFD, and ZLCEEGbiomark-
ers derived from the EEG frequency bands provide better
performance than EEG biomarkers derived from the whole
EEG record.
3.3. Discussions. The results of this study show that EEG
complexity-based measures provide a potentially useful way
to detect AD. The most characteristic feature caused by AD
is the reduction in EEG complexity [33–35, 37, 38, 40, 41]
compared to normal subjects. This is consistent with other
studies [35, 38, 43, 46, 56, 58, 62, 64, 80, 97, 98] and shows that
EEG complexity measures are potentially a good biomarker
for detecting AD.
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Figure 8: TsEn performance.
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Figure 10: LZC performance.
Table 3: Summary of the best performance indices for the three
complexity measures.
Method TsEn HFD LZC
Feature Delta Theta Theta Alpha Theta
EEG channel T4, O1, O2 F4 C4 T5, P3 C3
Sen.% 85.71 85.71 66.67 66.67 100
Spec.% 84.62 84.62 100 100 92.31
Acc.% 85 85 80 80 95𝐹-measure% 80 80 80 80 93.33
Error rate 0.15 0.15 0.2 0.2 0.05
MCC 0.685 0.685 0.667 0.667 0.9
FPR% 15.38 15.38 0 0 7.69
FNR% 14.29 14.29 33.33 33.33 0
PPV% 75 75 100 100 87.5
NPV% 91.67 91.67 66.67 66.67 100
Unlike previous studies, we found that the complexity
measures derived from the EEG frequency bands (i.e., delta,
theta, alpha, beta, and gamma) provide significantly better
performance in detecting AD than the complexity measures
derived from whole EEG records. This comes from the
greater differences between the complexity measures for AD
patients and normal subjects when they are derived from
the frequency bands compared to when they are derived
from whole record which is a desirable property of a good
biomarker.
In particular, we found that for the TsEn and HFD
complexity measures derived from the delta and theta bands
gave the best performance. For the delta band, three EEG
channels (T4, O1, and O2) gave the best performance. For the
theta band, F4 gave the best performance.
Similar results were obtained for the LZC complexity
measures, except that the best EEG channel was C3 for the
theta band. This is consistent with the findings of other
studies which suggested that AD starts from the back of the
brain and then spreads gradually to other parts of the brain
[5, 46, 99–101].This implies that it may be possible to use only
a small number of EEG channels to detect AD.
The findings of this study have a number of implications
for research to develop new and robust techniques for the
analysis of EEG to increase the contributions EEG makes to
the diagnosis of AD.
The results suggest that the three EEG complexity mea-
sures, derived from the EEG frequency bands, can detect AD
reliably (with sensitivity and specificity of >90%). Thus, EEG
complexity measures could provide a basis for developing
an accurate, low-cost, and easy to use tool to detect AD.
Although the results of the studies are consistent with pre-
vious studies, unlike previous studies, in this study, the com-
plexity measures are derived from EEG frequency bands (i.e.,
delta, theta, alpha, beta, and gamma).The results suggest that
deriving the complexity measures from the EEG frequency
bands is an important step for achieving robust biomarkers.
We found that AD patients have significantly lower
complexity measures for specific EEG frequency bands and
for specific EEG channels than normal subjects. This is
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consistent with findings in previous studies [33–35, 37, 38,
40, 41]. Thus, it may be possible to identify specific EEG
channels and specific frequency bands that may provide
the best biomarkers to detect AD. In situations where the
number of available channels is limited (e.g., when portable
EEG systems are used outside specialist centres), this may be
exploited to achieve a good performance.
It may be possible to enhance the performance of the
complexity-based approach further, by combining the three
complexity measures into a composite model. Given that the
three complexity measures are analysing different aspects of
the signal (e.g., entropy and fractal measures), integrating
them may lead to improved performance.
Our study has a number of limitations. At present, our
methods have been applied only to the detection of AD, the
most common form of dementia. A more detailed study is
necessary to evaluate the methods using a much larger and
diverse EEG datasets.This includes using the methods to dif-
ferentiate between normal,MCI, andAD subjects [57, 63, 73].
This study shows that the abnormalities caused by AD
can be detected by the complexitymeasures.However, similar
changes may be caused by other neurodegenerative diseases,
such as other types of dementia. To enhance the diagnostic
usefulness of the methods, it may be necessary to develop
them further to differentiate between dementias.
4. Conclusions
AD causes changes in the EEG due to loss of memory
and cognitive decline and these changes are thought to be
associated with functional disconnections among cortical
areas resulting from the death of brain cells. Therefore,
EEG analysis may provide valuable information about brain
dynamics in AD. AD causes a reduction in neuronal activity
of the brain and this may be reflected in EEG signals.
Nonlinear methods based on EEG complexity approaches
have shown promising results in detected changes in the
EEG thought to be due to AD. Therefore, EEG complexity
can potentially be a good biomarker for AD diagnosis. We
investigated three complexitymeasures, TsEn,HFD, and LZC
methods, derived from EEG frequency bands. We found that
AD patients have significantly lower TsEn, HFD, and LZC
values in specific EEG frequency bands and specific EEG
channels compared to normal subjects. This may provide
an effective way to discriminate between AD patients and
normal subjects. Future work will evaluate themethods using
larger and more diverse EEG datasets, including different
types of dementia.
Conflicts of Interest
The authors declare that there are no conflicts of interest
regarding the publication of this article
Acknowledgments
The first author would like to thank the Ministry of Higher
Education and Scientific Research (MoHESR), Iraq, for their
financial support. Financial support by the EPSRC is also
gratefully acknowledged.
References
[1] T. Harmony, T. Ferna´ndez, J. Gersenowies et al., “Specific EEG
frequencies signal general common cognitive processes as well
as specific task processes in man,” International Journal of
Psychophysiology, vol. 53, no. 3, pp. 207–216, 2004.
[2] C. Humpel, “Identifying and validating biomarkers for
Alzheimer’s disease,” Trends in Biotechnology, vol. 29, no. 1, pp.
26–32, 2011.
[3] W. H. Organization, WHO Mental Health Gap Action Pro-
gramme (mhGAP) 2008, 2014.
[4] ADNI, http://www.adni-info.org/.
[5] A. H. Al-Nuaimi, E. Jammeh, L. Sun, and E. Ifeachor, “Changes
in the EEG amplitude as a biomarker for early detection
of Alzheimer’s disease,” in Proceedings of the 38th Annual
International Conference of the IEEE Engineering in Medicine
and Biology Society, EMBC 2016, pp. 993–996, USA, August
2016.
[6] M. Prince, A. Wimo, M. Guerchet, G.-C. Ali, Y. Wu, and M.
Prina,World Alzheimer Report, 2015.
[7] M. Prince, A. Comas-Herrera, M. Knapp, M. Guerchet, and
M. Karagiannidou, “World Alzheimer Report 2016 Improving
healthcare for people living with dementia,” Coverage, Quality
and costs now and in the future, pp. 1–140, 2016.
[8] E. Jammeh, C. Carroll, S. Pearson et al., “Using NHS primary
care data to identify undiagnosed dementia,” Journal of Neurol-
ogy, Neurosurgery & Psychiatry, vol. 86, no. 11, pp. e4.134–e4,
2015.
[9] B. Michalowsky, T. Eichler, J. R. Thyrian et al., “Healthcare
resource utilization and cost in dementia: Are there differences
between patients screened positive for dementia with and those
without a formal diagnosis of dementia in primary care in
Germany?” International Psychogeriatrics, vol. 28, no. 3, pp.
359–369, 2016.
[10] M. Prince, R. Bryce, and C. Ferri,The benefits of early diagnosis
and intervention World Alzheimer Report 2011, Elsevier, 2011.
[11] G. Henderson, E. Ifeachor, N. Hudson et al., “Development and
assessment of methods for detecting dementia using the human
electroencephalogram,” IEEE Transactions on Biomedical Engi-
neering, vol. 53, no. 8, pp. 1557–1568, 2006.
[12] A. L. Sutton, Ed.,Alzheimer Disease Sourcebook, Omnigraphics:
Peter E. Ruffner, Detroit, USA, 5th edition, 2011.
[13] D. Galimberti and E. Scarpani, Biomarkers for Early Diagnosis
of Alzheimer’s Disease, Nova Biomedical Books, 2008.
[14] A. Association, 2017 Alzheimer’s disease facts and figures,
Alzheimer’s Dement, 2017.
[15] K. A. Jellinger, B. Janetzky, J. Attems, and E. Kienzl, “Biomarkers
for early diagnosis of Alzheimer disease: ’ALZheimer ASsoci-
ated gene’ - A new blood biomarker?” Journal of Cellular and
Molecular Medicine, vol. 12, no. 4, pp. 1094–1117, 2008.
[16] K. Ritchie and S. Lovestone, “The dementias,” The Lancet, vol.
360, no. 9347, pp. 1759–1766, 2002.
[17] R. A. Sperling, P. S. Aisen, L. A. Beckett et al., ““Toward defining
the preclinical stages of Alzheimer’s disease: Recommendations
from the National Institute on Aging-Alzheimer’s Association
workgroups on diagnostic guidelines for Alzheimer’s disease,”
Alzheimer’s Dement, vol. 7, no. 3, pp. 333-334, 2011.
10 Complexity
[18] A. Association, “2016 Alzheimer’s disease facts and figures,”
Alzheimer’s Dement, vol. 12, no. 4, pp. 459–509, 2016.
[19] M. D. Greicius, B. Krasnow, A. L. Reiss, and V. Menon,
“Functional connectivity in the resting brain: a network analysis
of the default mode hypothesis,” Proceedings of the National
Acadamy of Sciences of the United States of America, vol. 100,
no. 1, pp. 253–258, 2003.
[20] A. Gevins, M. E. Smith, L.McEvoy, andD. Yu, “High-resolution
EEGmapping of cortical activation related toworkingmemory:
effects of task difficulty, type of processing, and practice,”
Cerebral Cortex, vol. 7, no. 4, pp. 374–385, 1997.
[21] K. Sasaki, A. Nambu, T. Tsujimoto, R. Matsuzaki, S. Kyuhou,
and H. Gemba, “Studies on integrative functions of the human
frontal association cortex withMEG,” Cognitive Brain Research,
vol. 5, no. 1-2, pp. 165–174, 1996.
[22] T. Abeel, T. Helleputte, Y. Van de Peer, P. Dupont, and Y.
Saeys, “Robust biomarker identification for cancer diagnosis
with ensemble feature selection methods,” Bioinformatics, vol.
26, no. 3, pp. 392–398, 2009.
[23] A. Boucheham and M. Batouche, “Robust biomarker discovery
for cancer diagnosis based onmeta-ensemble feature selection,”
in Proceedings of the 2014 Science and Information Conference,
SAI 2014, pp. 452–460, UK, August 2014.
[24] A. H. Al-nuaimi, E. Jammeh, L. Sun, and E. Ifeachor, “Changes
in the Electroencephalogram as a Biomarker of Alzheimer’s
Disease,” in Proceedings of the Biosense Dementia 2017 - inter-
national workshop on biosensors for dementia from 13 – 14 June
2017, Plymouth University, Plymouth, UK, 2017.
[25] A. Cedazo-Minguez and B. Winblad, “Biomarkers for
Alzheimer’s disease and other forms of dementia: clinical needs,
limitations and future aspects,” Experimental Gerontology, vol.
45, no. 1, pp. 5–14, 2010.
[26] D. Ferreira, V. Jelic, L. Cavallin et al., “Electroencephalography
Is a Good Complement to Currently Established Dementia
Biomarkers,” Dementia and Geriatric Cognitive Disorders, vol.
42, no. 1-2, pp. 80–92, 2016.
[27] K. Blennow and H. Hampel, “CSF markers for incipient
Alzheimer’s disease,” The Lancet Neurology, vol. 2, no. 10, pp.
605–613, 2003.
[28] S. E. O’Bryant, M. M. Mielke, R. A. Rissman et al., “Blood-
based biomarkers in Alzheimer disease: Current state of the
science and a novel collaborative paradigm for advancing from
discovery to clinic,” Alzheimer’s & Dementia, vol. 13, no. 1, pp.
45–58, 2017.
[29] D. Ferreira, L. Perestelo-Pe´rez, E. Westman, L.-O. Wahlund,
A. Sarrisa, and P. Serrano-Aguilar, “Meta-review of CSF core
biomarkers in Alzheimer’s disease:The state-of-the-art after the
new revised diagnostic criteria,” Frontiers in AgingNeuroscience,
vol. 6, Article ID Article 47, 2014.
[30] M. Weiner and Z. Khachaturian, The use of MRI and PET
for clinical diagnosis of dementia and investigation of cognitive
impairment: a consensus report, Alzheimer’s Assoc., Chicago,
USA, 2005.
[31] B. Dubois, H. Hampel, H. H. Feldman et al., “Preclinical
Alzheimer’s disease: definition, natural history, and diagnostic
criteria,” Alzheimer’s & Dementia, vol. 12, no. 3, pp. 292–323,
2016.
[32] H. Jiang, M. P. White, M. D. Greicius, L. C. Waelde, and D.
Spiegel, “Brain activity and functional connectivity associated
with hypnosis,” Cerebral Cortex, vol. 27, no. 8, pp. 4083–4093,
2017.
[33] M. Signorino, E. Pucci, N. Belardinelli, G.Nolfe, and F.Angeleri,
“EEG spectral analysis in vascular and Alzheimer dementia,”
Electroencephalography and Clinical Neurophysiology, vol. 94,
no. 5, pp. 313–325, 1995.
[34] C. Besthorn, R. Zerfass, C. Geiger-Kabisch et al., “Discrimi-
nation of Alzheimers disease and normal aging by EEG data,”
Electroencephalography and Clinical Neurophysiology, vol. 103,
no. 2, pp. 241–248, 1997.
[35] A. H. Al-Nuaimi, E. Jammeh, L. Sun, and E. Ifeachor, “Tsallis
entropy as a biomarker for detection of Alzheimer’s disease,” in
Proceedings of the 37th Annual International Conference of the
IEEE Engineering in Medicine and Biology Society, EMBC 2015,
pp. 4166–4169, Italy, August 2015.
[36] A. Horvath, A. Szucs, G. Csukly, A. Sakovics, G. Stefanics, and
A. Kamondi, EEG and ERP biomarkers of Alzheimer’s disease: a
critical review, EEG and ERP biomarkers of Alzheimer’s disease,
a critical review.
[37] D. Moretti, C. Fracassi, M. Pievani et al., “Increase of
theta/gamma ratio is associated with memory impairment,”
Clinical Neurophysiology, vol. 120, no. 2, pp. 295–303, 2009.
[38] J. Jeong, “EEG dynamics in patients with Alzheimer’s disease,”
Clinical Neurophysiology, vol. 115, no. 7, pp. 1490–1505, 2004.
[39] Y. A. L. Pijnenburg, Y. Vd Made, A. M. van Cappellen van
Walsum, D. L. Knol, P. Scheltens, and C. J. Stam, “EEG
synchronization likelihood in mild cognitive impairment and
Alzheimer’s disease during a working memory task,” Clinical
Neurophysiology, vol. 115, no. 6, pp. 1332–1339, 2004.
[40] M. Ishikawa, K. Doya, H. Miyamoto, and T. Yamakawa,
“Dynamical nonstationarity analysis of resting EEGs in
Alzheimer’s disease,” in Proceedings of the International
Conference on Neural Information Processing, pp. 921–929, 2007.
[41] J. Dauwels, F.-B. Vialatte, and A. Cichocki, “On the early
diagnosis of Alzheimer’s disease from EEG signals: a mini-
review,” in Advances in Cognitive Neurodynamics (II), pp. 709–
716, Springer, 2011.
[42] C. Babiloni, G. Binetti, E. Cassetta et al., “Sources of cortical
rhythms change as a function of cognitive impairment in patho-
logical aging: amulticenter study,”Clinical Neurophysiology, vol.
117, no. 2, pp. 252–268, 2006.
[43] D. Aba´solo, R. Hornero, C. Go´mez, M. Garc´ıa, and M. Lo´pez,
“Analysis of EEG background activity in Alzheimer’s disease
patients with Lempel-Ziv complexity and central tendency
measure,”Medical Engineering & Physics, vol. 28, no. 4, pp. 315–
322, 2006.
[44] C. Babiloni, C. Del Percio, F. Vecchio et al., “Alpha, beta
and gamma electrocorticographic rhythms in somatosensory,
motor, premotor and prefrontal cortical areas differ in move-
ment execution and observation in humans,” Clinical Neuro-
physiology, vol. 127, no. 1, pp. 641–654, 2016.
[45] G. G. Yener, D. D. Emek-Savas¸, R. Lizio et al., “Frontal delta
event-related oscillations relate to frontal volume in mild cog-
nitive impairment and healthy controls,” International Journal
of Psychophysiology, vol. 103, pp. 110–117, 2016.
[46] A. H. Al-Nuaimi, E. Jammeh, L. Sun, and E. Ifeachor, “Higuchi
fractal dimension of the electroencephalogram as a biomarker
for early detection of Alzheimer’s disease,” in Proceedings of
the 2017 39th Annual International Conference of the IEEE
Engineering in Medicine and Biology Society (EMBC), pp. 2320–
2324, Jeju Island, South Korea, July 2017.
[47] D. Aba´solo, R. Hornero, P. Espino, J. Poza, C. I. Sa´nchez, and
R. De La Rosa, “Analysis of regularity in the EEG background
Complexity 11
activity of Alzheimer’s disease patients with Approximate
Entropy,”Clinical Neurophysiology, vol. 116, no. 8, pp. 1826–1834,
2005.
[48] H. Kantz and T. Schreiber, Nonlinear Time Series Analysis,
Cambridge University Press, 2nd edition, 2004.
[49] A. Lempel and J. Ziv, “On the Complexity of Finite Sequences,”
IEEE Transactions on Information Theory, vol. 22, no. 1, pp. 75–
81, 1976.
[50] G. Tononi, G. M. Edelman, and O. Sporns, “Complexity and
coherency: integrating information in the brain,” Trends in
Cognitive Sciences, vol. 2, no. 12, pp. 474–484, 1998.
[51] R. Wackerbauer, A. Witt, H. Atmanspacher, J. Kurths, and
H. Scheingraber, “A comparative classification of complexity
measures,” Chaos, Solitons & Fractals, vol. 4, no. 1, pp. 133–173,
1994.
[52] C. Besthorn, H. Sattel, C. Geiger-Kabisch, R. Zerfass, and
H. Fo¨rstl, “Parameters of EEG dimensional complexity in
Alzheimer’s disease,” Electroencephalography and Clinical Neu-
rophysiology, vol. 95, no. 2, pp. 84–89, 1995.
[53] A. P. Burgess, J. Rehman, and J. D.Williams, “Changes in neural
complexity during the perception of 3D images using random
dot stereograms,” International Journal of Psychophysiology, vol.
48, no. 1, pp. 35–42, 2003.
[54] F. Gu, X. Meng, E. Shen, and Z. Cai, “Can we measure
consciousness with EEG complexities?” International Journal of
Bifurcation and Chaos, vol. 13, no. 3, pp. 733–742, 2003.
[55] H. Adeli and S. Ghosh-Dastidar, Automated EEG-based diag-
nosis of neurological disorders: Inventing the future of neurology,
CRC Press, 2010.
[56] J. C. McBride, X. Zhao, N. B. Munro et al., “Spectral and com-
plexity analysis of scalp EEG characteristics for mild cognitive
impairment and early Alzheimer’s disease,” Computer Methods
and Programs in Biomedicine, vol. 114, no. 2, pp. 153–163, 2014.
[57] J. Dauwels, K. Srinivasan, M. Ramasubba Reddy et al., “Slowing
and loss of complexity in Alzheimer’s EEG: Two sides of the
same coin?” International Journal of Alzheimer’s Disease, Article
ID 539621, 2011.
[58] P. Zhao, P. Van-Eetvelt, C.Goh,N.Hudson, S.Wimalaratna, and
E. Ifeachor, “Characterization of EEGs in Alzheimer’s disease
using information theoreticmethods,” in Proceedings of the 29th
Annual International Conference of the IEEEon Engineering in
Medicine and Biology Society (EMBC ’07), pp. 5127–5131, Lyon,
France, August 2007.
[59] B. Hamadicharef, C. Guan, N. Hudson, E. C. Ifeachor, and S.
Wimalaratna, “Performance evaluation and fusion of methods
for early detection of Alzheimer Disease,” in Proceedings of
the 1st International Conference on BioMedical Engineering and
Informatics (BMEI ’08), pp. 347–351, Sanya, China, May 2008.
[60] J. Escudero, D. Aba´solo, R. Hornero, P. Espino, and M. Lo´pez,
“Analysis of electroencephalograms in Alzheimer’s disease
patients with multiscale entropy,” Physiological Measurement,
vol. 27, no. 11, article 004, p. 1091, 2006.
[61] M. Zanin, L. Zunino, O. A. Rosso, and D. Papo, “Permutation
entropy and itsmain biomedical and econophysics applications:
a review,” Entropy, vol. 14, no. 8, pp. 1553–1577, 2012.
[62] T. J. De Bock, S. Das, M. Mohsin et al., “Early detection of
Alzheimer’s disease using nonlinear analysis of EEG via Tsallis
entropy,” in Proceedings of the 2010 Biomedical Sciences and
Engineering Conference (BSEC), pp. 1–4, Oak Ridge, TN, USA,
2010.
[63] J. Dauwels, F. Vialatte, and A. Cichocki, “Diagnosis of
Alzheimer’s disease from EEG signals: where are we standing?”
Current Alzheimer Research, vol. 7, no. 6, pp. 487–505, 2010.
[64] C. Coronel, H. Garn, M. Waser et al., “Quantitative EEG
markers of entropy and auto mutual information in relation
to MMSE scores of probable Alzheimer’s disease patients,”
Entropy, vol. 19, no. 3, article no. 130, 2017.
[65] R. Sneddon, W. R. Shankle, J. Hara, A. Rodriquez, D. Hoffman,
andU. Saha, “EEGDetection of EarlyAlzheimer’sDiseaseUsing
Psychophysical Tasks,” Clinical EEG and Neuroscience, vol. 36,
no. 3, pp. 141–150, 2005.
[66] H. Garn, M. Waser, M. Deistler et al., “Quantitative EEG
markers relate to Alzheimer’s disease severity in the Prospective
Dementia Registry Austria (PRODEM),” Clinical Neurophysiol-
ogy, vol. 126, no. 3, pp. 505–513, 2015.
[67] D. Aba´solo, S. Simons, R.Morgado da Silva, G. Tononi, andV. V.
Vyazovskiy, “Lempel-Ziv complexity of cortical activity during
sleep and waking in rats,” Journal of Neurophysiology, vol. 113,
no. 7, pp. 2742–2752, 2015.
[68] M. W. Rivolta, M. Migliorini, M. Aktaruzzaman, R. Sassi, and
A. M. Bianchi, “Effects of the series length on Lempel-Ziv
Complexity during sleep,” inProceedings of the 2014 36thAnnual
International Conference of the IEEE Engineering in Medicine
and Biology Society, EMBC 2014, pp. 693–696, USA, August
2014.
[69] X.-S. Zhang, R. J. Roy, and E. W. Jensen, “EEG complexity as a
measure of depth of anesthesia for patients,” IEEE Transactions
on Biomedical Engineering, vol. 48, no. 12, pp. 1424–1433, 2001.
[70] M. Aboy, R. Hornero, D. Aba´solo, and D. A´lvarez, “Interpreta-
tion of the Lempel-Ziv complexity measure in the context of
biomedical signal analysis,” IEEE Transactions on Biomedical
Engineering, vol. 53, no. 11, pp. 2282–2288, 2006.
[71] S. Simons and D. Aba´solo, “Distance-based Lempel-Ziv com-
plexity for the analysis of electroencephalograms in patients
with Alzheimer’s disease,” Entropy, vol. 19, no. 3, Article ID
e19030129, 2017.
[72] R. Hornero, D. Aba´solo, J. Escudero, and C. Go´mez, “Nonlinear
analysis of electroencephalogram and magnetoencephalogram
recordings in patients with Alzheimer’s disease,” Philosophical
Transactions of the Royal Society A: Mathematical, Physical &
Engineering Sciences, vol. 367, no. 1887, pp. 317–336, 2009.
[73] R. Hornero, J. Escudero, A. Ferna´ndez, J. Poza, and C. Go´mez,
“Spectral and nonlinear analyses of MEG background activity
in patients with Alzheimer’s disease,” IEEE Transactions on
Biomedical Engineering, vol. 55, no. 6, pp. 1658–1665, 2008.
[74] A. Fernandez, R. Hornero, C. Go´mez et al., “Complexity
analysis of spontaneous brain activity in alzheimer disease and
mild cognitive impairment: An MEG study,” Alzheimer Disease
& Associated Disorders, vol. 24, no. 2, pp. 182–189, 2010.
[75] A. Accardo, M. Affinito, M. Carrozzi, and F. Bouquet, “Use
of the fractal dimension for the analysis of electroencephalo-
graphic time series,” Biological Cybernetics, vol. 77, no. 5, pp.
339–350, 1997.
[76] H. Preißl, W. Lutzenberger, F. Pulvermu¨ller, and N. Birbaumer,
“Fractal dimensions of short EEG time series in humans,”
Neuroscience Letters, vol. 225, no. 2, pp. 77–80, 1997.
[77] T. Higuchi, “Approach to an irregular time series on the basis of
the fractal theory,” Physica D: Nonlinear Phenomena, vol. 31, no.
2, pp. 277–283, 1988.
[78] R. Esteller, G. Vachtsevanos, J. Echauz, and B. Litt, “A com-
parison of fractal dimension algorithms using synthetic and
12 Complexity
experimental data,” in Proceedings of the IEEE International
Symosium on Circuits and Systems (ISCAS ’99), vol. 3, pp. 199–
202, IEEE, Orlando, Fla, USA, July 1999.
[79] C. Go´mez, A´. Mediavilla, R. Hornero, D. Aba´solo, and A.
Ferna´ndez, “Use of the Higuchi’s fractal dimension for the
analysis of MEG recordings from Alzheimer’s disease patients,”
Medical Engineering & Physics, vol. 31, no. 3, pp. 306–313, 2009.
[80] F. M. Smits, C. Porcaro, C. Cottone, A. Cancelli, P. M. Rossini,
and F. Tecchio, “Electroencephalographic fractal dimension in
healthy ageing and Alzheimer’s disease,” PLoS ONE, vol. 11, no.
2, Article ID e0149587, 2016.
[81] T. Staudinger and R. Polikar, “Analysis of complexity based
EEG features for the diagnosis of Alzheimer’s disease,” in
Proceedings of the 33rd Annual International Conference of the
IEEE Engineering in Medicine and Biology Society, EMBS 2011,
pp. 2033–2036, USA, September 2011.
[82] L. Hirsch and R. Brenner, Atlas of EEG in critical care, John
Wiley & Sons, 2011.
[83] S. Sanei,Adaptive processing of brain signals, JohnWiley & Sons,
2013.
[84] M. F. Folstein, S. E. Folstein, and P. R. McHugh, ““Mini mental
state”. A practical method for grading the cognitive state of
patients for the clinician,” Journal of Psychiatric Research, vol.
12, no. 3, pp. 189–198, 1975.
[85] E. Strauss, E. M. S. Sherman, and O. Spreen, A compendium of
neuropsychological tests: Administration, norms, and commen-
tary, American Chemical Society, 2006.
[86] A. L. Benton, Revised Visual Retention Test: Clinical and Experi-
mental Applications, Psychological Corporation, New York, NY,
USA, 1974.
[87] G. A. Talland and M. Ekdahl, “Psychological studies of kor-
sakoff ’s psychosis: IV.The rate andmode of forgetting narrative
material,” The Journal of Nervous and Mental Disease, vol. 129,
no. 4, pp. 391–404, 1959.
[88] J. Tuqan and P. P. Vaidyanathan, “Optimum low cost two
channel IIR orthonormal filter bank,” in Proceedings of the 1997
IEEE International Conference on Acoustics, Speech, and Signal
Processing, ICASSP, pp. 2425–2428, April 1997.
[89] M. Gell-Mann and C. Tsallis, Nonextensive entropy: interdisci-
plinary applications, Oxford University Press, 2004.
[90] C. Go´mez, D. Aba´solo, J. Poza, A. Ferna´ndez, and R. Hornero,
“MEG analysis in Alzheimer’s disease computing approximate
entropy for different frequency bands,” inProceedings of the 2010
32nd Annual International Conference of the IEEE Engineering
in Medicine and Biology Society, EMBC’10, pp. 2379–2382,
Argentina, September 2010.
[91] J. Ramı´rez, J. M. Go´rriz, D. Salas-Gonzalez et al., “Computer-
aided diagnosis of Alzheimer’s type dementia combining sup-
port vector machines and discriminant set of features,” Infor-
mation Sciences, vol. 237, pp. 59–72, 2013.
[92] R. Chaves, J. Ramı´rez, J. M. Go´rriz et al., “SVM-based
computer-aided diagnosis of the Alzheimer’s disease using t-
test NMSE feature selection with feature correlation weighting,”
Neuroscience Letters, vol. 461, no. 3, pp. 293–297, 2009.
[93] J. M. Go´rriz, J. Ramı´rez, A. Lassl et al., “Automatic computer
aided diagnosis tool using component-based SVM,” in Proceed-
ings of the 2008 IEEE Nuclear Science Symposium Conference
Record, NSS/MIC 2008, pp. 4392–4395, Germany, October
2008.
[94] A. So, D. Hooshyar, K. W. Park, and H. S. Lim, “Early diagnosis
of dementia from clinical data bymachine learning techniques,”
Applied Sciences (Switzerland), vol. 7, no. 7, article no. 651, 2017.
[95] S. Raschka, An Overview of General Performance Metrics of
Binary Classifier Systems, 2014, arXiv1410.5330.
[96] D. M. W. Powers, “Evaluation: From Precision, Recall and
F-Factor to ROC, Informedness, Markedness & Correlation,
School of Informatics and Engineering, Flinders University,
Adelaide, Australia,” Journal of Machine Learning Technologies,
vol. 2, no. 1, pp. 37–63, 2011.
[97] S. Simons, D. Abasolo, and M. Hughes, “Investigation of
Alzheimer’s disease EEG frequency components with Lempel-
Ziv complexity,” in Proceedings of the 6th European Conference
of the International Federation for Medical and Biological Engi-
neering, MBEC 2014, pp. 46–49, Croatia, September 2014.
[98] N. N. Kulkarni and V. K. Bairagi, “Extracting Salient Features
for EEG-based Diagnosis of Alzheimer’s Disease Using Support
VectorMachine Classifier,” IETE Journal of Research, vol. 63, no.
1, pp. 11–22, 2017.
[99] D. V. Moretti, “Theta and alpha eeg frequency interplay in sub-
jects withmild cognitive impairment: Evidence fromEEG,MRI
and spect brain modifications,” Frontiers in Aging Neuroscience,
vol. 7, article no. 31, 2015.
[100] C. Babiloni, R. Ferri, G. Binetti et al., “Directionality of EEG
synchronization in Alzheimer’s disease subjects,” Neurobiology
of Aging, vol. 30, no. 1, pp. 93–102, 2009.
[101] U. A. Khan, L. Liu, F. A. Provenzano et al., “Molecular drivers
and cortical spread of lateral entorhinal cortex dysfunction in
preclinical Alzheimer’s disease,”Nature Neuroscience, vol. 17, no.
2, pp. 304–311, 2014.
Hindawi
www.hindawi.com Volume 2018
Mathematics
Journal of
Hindawi
www.hindawi.com Volume 2018
Mathematical Problems 
in Engineering
Applied Mathematics
Journal of
Hindawi
www.hindawi.com Volume 2018
Probability and Statistics
Hindawi
www.hindawi.com Volume 2018
Journal of
Hindawi
www.hindawi.com Volume 2018
Mathematical Physics
Advances in
Complex Analysis
Journal of
Hindawi
www.hindawi.com Volume 2018
Optimization
Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
Engineering  
 Mathematics
International Journal of
Hindawi
www.hindawi.com Volume 2018
Operations Research
Advances in
Journal of
Hindawi
www.hindawi.com Volume 2018
Function Spaces
Abstract and 
Applied Analysis
Hindawi
www.hindawi.com Volume 2018
International 
Journal of 
Mathematics and 
Mathematical 
Sciences
Hindawi
www.hindawi.com Volume 2018
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2013www.hindawi.com
The Scientific 
World Journal
8
Hindawi
www.hindawi.com Volume 2018
Numerical Analysis
Advances in Discrete Dynamics in 
Nature and Society
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com
Dierential Equations
International Journal of
Volume 2018
Hindawi
www.hindawi.com Volume 2018
Decision Sciences
Advances in
Hindawi
www.hindawi.com Volume 2018
Analysis
International Journal of
Hindawi
www.hindawi.com Volume 2018
Stochastic Analysis
International Journal of
Submit your manuscripts at
www.hindawi.com
